Latest Halozyme Therapeutics (HALO) Headlines
'Mad Money' Lightning Round: Boston Scientific Is a Favorite
at The Street - Wed Mar 12, 5:00AM CDT
Cramer also loves Occidental Petroleum but he's not recommending Bed Bath & Beyond.
Jim Cramer's 'Mad Money' Recap: Silver Lining Playbook
at The Street - Tue Mar 11, 7:04PM CDT
The markets are a healthier place today, even though most investors lost money, Cramer says.
Halozyme Therapeutics To Present At The Barclays 2014 Global Healthcare Conference
PR Newswire - Wed Mar 05, 7:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Barclays 2014 Global Healthcare Conference in Miami, FL on March 11, 2014 at 2:00 p.m. ET/11:00 a.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
Halozyme's Q4 Loss Wider-Than-Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 1:43PM CST
Halozyme Therapeutics, Inc. (HALO) reported a fourth quarter loss of 19 cents per share, much wider than the year-ago loss of 4 cents per share and the Zacks Consensus Estimate of a loss of 17 cents per share. Lower revenues and higher costs led to the year-over-year increase in loss.
Cara Therapeutics (CARA) Zooms: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:39AM CST
Cara Therapeutics Inc. was a big mover last session, as its shares surged over 12% on the day.
bluebird bio (BLUE) Zooms: Stock Up 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 7:51AM CST
bluebird bio, Inc. (BLUE) was a big mover last session, as its shares surged over 7% on the day.
Halozyme Therapeutics reports net loss of USD22.0m in Q4 2013
M2 - Fri Feb 28, 4:08AM CST
US-based biopharmaceutical company Halozyme Therapeutics (Nasdaq GS:HALO) disclosed on Thursday its net loss of USD22.0m (USD0.19 per share) for the fourth quarter ended 31 December 2013.
Halozyme Reports Fourth Quarter And Year End 2013 Financial Results
PR Newswire - Thu Feb 27, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2013. Financial highlights for the fourth quarter include revenues of $12.5 million and a net loss of $22.0 million, or $0.19 per share. This compares to revenues of $21.8 million and a net loss of $4.4 million, or $0.04 per share, for the fourth quarter of 2012. Financial highlights for the full year 2013 include revenues of $54.8 million and a net loss of $83.5 million, or $0.74 per share. This compares to revenues of $42.3 million and a net loss of $53.6 million, or $0.48 per share, in the prior year.
Halozyme Therapeutics To Present At The Cowen And Company 34th Annual Healthcare Conference
PR Newswire - Tue Feb 25, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Cowen and Company 34th Annual Healthcare Conference in Boston, MA on Tuesday, March 4, 2014 at 9:20 a.m. ET/6:20 a.m. PT. David Ramsay, Chief Financial Officer, will provide a corporate overview.
Halozyme to Host Fourth Quarter and 2013 Year-End Financial Results Conference Call
PR Newswire - Thu Feb 20, 3:30PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2013 on Thursday, February 27, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the fourth quarter and year-ended December 31, 2013.
Cirrus Aircraft Deliveries in 2013 Drive Strongest Performance in Five Years
PR Newswire - Wed Feb 19, 10:00AM CST
Cirrus Aircraft today announced that in 2013 it delivered 276 new aircraft, nearly a 10 percent increase over 2012, marking its best aircraft shipment performance since 2008. With these results, Cirrus Aircraft's annual market share has grown to an all-time high of 37 percent and the SR22/22T model remains the best-selling four- or five-seat airplane for the 11th year in a row.
Halozyme Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
PR Newswire - Mon Feb 10, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the closing of its previously announced public offering of 8,846,153 shares of common stock, including 1,153,846 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $13.00 per share. Halozyme's net proceeds from this offering are expected to be approximately $107.8 million, after deducting the underwriting discounts and commissions and estimated expenses.
Halozyme Therapeutics Inc prices public offering at USD13.00 per share
M2 - Wed Feb 05, 4:47AM CST
Biopharmaceutical company Halozyme Therapeutics Inc (NasdaqGS:HALO) announced on Tuesday that it has priced a public offering of 7,692,307 shares of its common stock.
Halozyme Therapeutics Prices Public Offering Of Common Stock
PR Newswire - Tue Feb 04, 7:20PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the pricing of its previously announced underwritten public offering of 7,692,307 shares of its common stock at a public offering price of $13.00 per share. All of the shares in the offering are being sold by Halozyme. The offering is expected to close on February 10, 2014, subject to customary closing conditions. In addition, Halozyme has granted the underwriters a 30-day option to purchase up to an additional 1,153,846 shares of common stock.
SmarTrend Watching for Potential Rebound in Shares of Halozyme Therapeutics After 6.48% Loss
Comtex SmarTrend(R) - Tue Feb 04, 5:55PM CST
Halozyme Therapeutics (NASDAQ:HALO) traded in a range yesterday that spanned from a low of $13.65 to a high of $14.74. Yesterday, the shares fell 6.5%, which took the trading range below the 3-day low of $14.46 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Halozyme Therapeutics Inc commences public offering of USD100m common shares
M2 - Tue Feb 04, 3:19AM CST
Biopharmaceutical company Halozyme Therapeutics Inc (NasdaqGS:HALO) reported on Monday public offering the start of USD100m of shares of its common stock.
Halozyme Therapeutics Announces Public Offering Of Common Stock
PR Newswire - Mon Feb 03, 3:01PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares in the offering are to be sold by Halozyme. Halozyme intends to grant the underwriters a 30-day option to purchase up to $15,000,000 of additional shares. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Good News for Halozyme - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 27, 5:10PM CST
The CHMP gave a positive opinion on the approval of Roche's MabThera using Halozyme's rHuPH20.
Halozyme Therapeutics receives positive opinion from CHMP for approval of MabThera in Europe
M2 - Mon Jan 27, 8:09AM CST
US-based biopharmaceutical company Halozyme Therapeutics Inc (HALO) said on Friday that the EU Committee for Medicinal Products for Human Use (CHMP) recommended Roche's subcutaneous (SC) formulation of MabThera (rituximab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL) in Europe.
Halozyme Announces Positive Opinion From CHMP For European Approval Of Roche's MabThera SC
PR Newswire - Fri Jan 24, 10:32AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve Roche's subcutaneous (SC) formulation of MabThera® (rituximab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL).
'Mad Money' Lightning Round: Boston Scientific Is a Favorite
at The Street - Wed Mar 12, 5:00AM CDT
Cramer also loves Occidental Petroleum but he's not recommending Bed Bath & Beyond.
Jim Cramer's 'Mad Money' Recap: Silver Lining Playbook
at The Street - Tue Mar 11, 7:04PM CDT
The markets are a healthier place today, even though most investors lost money, Cramer says.
Halozyme Therapeutics To Present At The Barclays 2014 Global Healthcare Conference
PR Newswire - Wed Mar 05, 7:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Barclays 2014 Global Healthcare Conference in Miami, FL on March 11, 2014 at 2:00 p.m. ET/11:00 a.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
Halozyme's Q4 Loss Wider-Than-Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 1:43PM CST
Halozyme Therapeutics, Inc. (HALO) reported a fourth quarter loss of 19 cents per share, much wider than the year-ago loss of 4 cents per share and the Zacks Consensus Estimate of a loss of 17 cents per share. Lower revenues and higher costs led to the year-over-year increase in loss.
Cara Therapeutics (CARA) Zooms: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:39AM CST
Cara Therapeutics Inc. was a big mover last session, as its shares surged over 12% on the day.
bluebird bio (BLUE) Zooms: Stock Up 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 7:51AM CST
bluebird bio, Inc. (BLUE) was a big mover last session, as its shares surged over 7% on the day.
Halozyme Therapeutics reports net loss of USD22.0m in Q4 2013
M2 - Fri Feb 28, 4:08AM CST
US-based biopharmaceutical company Halozyme Therapeutics (Nasdaq GS:HALO) disclosed on Thursday its net loss of USD22.0m (USD0.19 per share) for the fourth quarter ended 31 December 2013.
Halozyme Reports Fourth Quarter And Year End 2013 Financial Results
PR Newswire - Thu Feb 27, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2013. Financial highlights for the fourth quarter include revenues of $12.5 million and a net loss of $22.0 million, or $0.19 per share. This compares to revenues of $21.8 million and a net loss of $4.4 million, or $0.04 per share, for the fourth quarter of 2012. Financial highlights for the full year 2013 include revenues of $54.8 million and a net loss of $83.5 million, or $0.74 per share. This compares to revenues of $42.3 million and a net loss of $53.6 million, or $0.48 per share, in the prior year.
Halozyme Therapeutics To Present At The Cowen And Company 34th Annual Healthcare Conference
PR Newswire - Tue Feb 25, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Cowen and Company 34th Annual Healthcare Conference in Boston, MA on Tuesday, March 4, 2014 at 9:20 a.m. ET/6:20 a.m. PT. David Ramsay, Chief Financial Officer, will provide a corporate overview.
Halozyme to Host Fourth Quarter and 2013 Year-End Financial Results Conference Call
PR Newswire - Thu Feb 20, 3:30PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2013 on Thursday, February 27, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the fourth quarter and year-ended December 31, 2013.
Cirrus Aircraft Deliveries in 2013 Drive Strongest Performance in Five Years
PR Newswire - Wed Feb 19, 10:00AM CST
Cirrus Aircraft today announced that in 2013 it delivered 276 new aircraft, nearly a 10 percent increase over 2012, marking its best aircraft shipment performance since 2008. With these results, Cirrus Aircraft's annual market share has grown to an all-time high of 37 percent and the SR22/22T model remains the best-selling four- or five-seat airplane for the 11th year in a row.
Halozyme Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
PR Newswire - Mon Feb 10, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the closing of its previously announced public offering of 8,846,153 shares of common stock, including 1,153,846 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $13.00 per share. Halozyme's net proceeds from this offering are expected to be approximately $107.8 million, after deducting the underwriting discounts and commissions and estimated expenses.
Halozyme Therapeutics Inc prices public offering at USD13.00 per share
M2 - Wed Feb 05, 4:47AM CST
Biopharmaceutical company Halozyme Therapeutics Inc (NasdaqGS:HALO) announced on Tuesday that it has priced a public offering of 7,692,307 shares of its common stock.
Halozyme Therapeutics Prices Public Offering Of Common Stock
PR Newswire - Tue Feb 04, 7:20PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the pricing of its previously announced underwritten public offering of 7,692,307 shares of its common stock at a public offering price of $13.00 per share. All of the shares in the offering are being sold by Halozyme. The offering is expected to close on February 10, 2014, subject to customary closing conditions. In addition, Halozyme has granted the underwriters a 30-day option to purchase up to an additional 1,153,846 shares of common stock.
SmarTrend Watching for Potential Rebound in Shares of Halozyme Therapeutics After 6.48% Loss
Comtex SmarTrend(R) - Tue Feb 04, 5:55PM CST
Halozyme Therapeutics (NASDAQ:HALO) traded in a range yesterday that spanned from a low of $13.65 to a high of $14.74. Yesterday, the shares fell 6.5%, which took the trading range below the 3-day low of $14.46 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Halozyme Therapeutics Inc commences public offering of USD100m common shares
M2 - Tue Feb 04, 3:19AM CST
Biopharmaceutical company Halozyme Therapeutics Inc (NasdaqGS:HALO) reported on Monday public offering the start of USD100m of shares of its common stock.
Halozyme Therapeutics Announces Public Offering Of Common Stock
PR Newswire - Mon Feb 03, 3:01PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares in the offering are to be sold by Halozyme. Halozyme intends to grant the underwriters a 30-day option to purchase up to $15,000,000 of additional shares. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Good News for Halozyme - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 27, 5:10PM CST
The CHMP gave a positive opinion on the approval of Roche's MabThera using Halozyme's rHuPH20.
Halozyme Therapeutics receives positive opinion from CHMP for approval of MabThera in Europe
M2 - Mon Jan 27, 8:09AM CST
US-based biopharmaceutical company Halozyme Therapeutics Inc (HALO) said on Friday that the EU Committee for Medicinal Products for Human Use (CHMP) recommended Roche's subcutaneous (SC) formulation of MabThera (rituximab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL) in Europe.
Halozyme Announces Positive Opinion From CHMP For European Approval Of Roche's MabThera SC
PR Newswire - Fri Jan 24, 10:32AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve Roche's subcutaneous (SC) formulation of MabThera® (rituximab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL).
